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Abstract
Background: The emergence of imipenem-resistant Pseudomonas aeruginosa (IRPA) has become a great concern
worldwide. The aim of this study was to investigate resistance mechanisms associated with bloodstream isolated
IRPA strains in Taiwan.
Results: A total of 78 non-duplicated IRPA isolates were isolated from patients with bloodstream infection. The average
prevalence of imipenem-resistance in those isolates was 5.9 % during a 10-year longitudinal surveillance in Taiwan.
PFGE results showed high clonal diversity among the 78 isolates. VIM-2, VIM-3, OXA-10, and OXA-17 β-lactamases were
identified in 2 (2.6 %), 3 (3.8 %), 2 (2.6 %), and 1 (1.3 %) isolates, respectively. Active efflux pumps, AmpC β-lactamase
overproduction, and extended-spectrum AmpC cephalosporinases (ESACs) were found in 58 (74.4 %), 25 (32.1 %) and 15
(19.2 %) of IRPA isolates, respectively. oprD mutations with amino acid substitution, shortened putative loop L7, premature
stop codon caused by point mutation, frameshift by nucleotide insertion or deletion, and interruption by insertion
sequence were found in 19 (24.4 %), 18 (23.1 %), 15 (19.2 %), 14 (17.9 %), and 10 (12.8 %) of isolates, respectively.
Conclusions: This study suggests that alterations in the OprD protein and having an active efflux pump are the main
mechanisms associated with bloodstream isolated IRPA. Overproduction of AmpC, ESACs, and the presence of VIM- and
OXA-type β-lactamases play additional roles in reduced susceptibility to imipenem in P. aeruginosa isolates in Taiwan.
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Background
Pseudomonas aeruginosa is one of the most important
nosocomial pathogens, which colonizes patients with
trauma or a breach by tracheostomy, catheters, surgery,
or severe burns. It is also the major cause of chronic
lung infections in individuals with cystic fibrosis [1].
Treatment of infections caused by P. aeruginosa has be-
come more challenging because of its resistance to many
antimicrobial agents [2, 3]. Carbapenems (including
imipenem, meropenem, and doripenem) remain the
principal antimicrobial agents for treatment of serious
infections, such as nosocomial pneumonia, serious noso-
comial intra-abdominal infection and septicemia caused
by P. aeruginosa [4].
Extensive use of carbapenems has contributed to the
emergence of carbapenem-resistant P. aeruginosa (CRPA),
and the increasing incidence of resistance to carbapenems
in P. aeruginosa has become a global issue [5–10].
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Surveillance of antimicrobial susceptibility by the Euro-
pean Centre for Disease Prevention and Control reported
that the average rate of resistance of P. aeruginosa against
carbapenems was 17.1 % [11].
The acquisition of carbapenem-hydrolyzing β-lactamases
(such as KPC, AIM, DIM, GIM, IMP, NDM, SPM, VIM,
and OXA), overexpression of chromosome-encoded AmpC
β-lactamase, extended-spectrum AmpC cephalosporinases
(ESACs), reduction of permeability of the outer membrane
protein OprD, and overexpression of the major resistance-
nodulation-division (RND) efflux pump systems (MexAB-
OprM, MexCD-OprJ, MexEF-OprN, and MexXY-OprM),
are all involved in carbapenem resistance in P. aeruginosa
[2, 12, 13]. Most AmpC-type β-lactamases naturally pro-
duced by Gram-negative organisms hydrolyse amino- and
ureido-penicillins, cephamycins (cefoxitin and cefotetan)
and, to a lesser extent, oxyimino-cephalosporins (such as
ceftazidime) and monobactams [14]. In contrast, ESACs
confer reduced susceptibility to cephalosporins and carba-
penems [15, 16].
The present study was conducted to investigate the
prevalence and characteristics of bloodstream isolated
imipenem-resistant P. aeruginosa (IRPA) collected be-
tween 2000 and 2010. Our findings demonstrated that
the prevalence of imipenem resistance in bacteremic P.
aeruginosa remains low (5.9 %) in Taiwan. Mutations in
oprD and production of an active efflux pump are the
major causes of imipenem resistance in P. aeruginosa,
followed by overproduction of AmpC β-lactamase,
ESACs, and the acquisition of VIM and OXA.
Methods
Sampling and isolation of P. aeruginosa
Bacteremic P. aeruginosa isolates were recovered in two
Taiwanese University hospitals, January 2000 to February
2010. The Ethics Committee of National Cheng Kung
University Hospital (NCKUH) approved that no formal
ethical approval was needed to use these clinically ob-
tained materials, because the strains were remnant from
patient samples, and the data were analyzed anonym-
ously. P. aeruginosa was identified in clinical laboratory
by colony morphology, Gram stain, biochemical tests,
and the Vitek system (bioMérieux, Marcy l’Etoile,
France) according to the manufacturer’s recommenda-
tions. Susceptibility to imipenem for P. aeruginosa iso-
lates was determined by the disk diffusion method
(imipenem, 10 μg/disc) on Mueller-Hinton (MH) agar
based on the CLSI guidelines [17]. A total of 78 bacteremic
imipenem-resistant P. aeruginosa isolates were selected for
further analysis.
Antimicrobial susceptibility testing
Minimal inhibitory concentrations (MICs) of amikacin
(Sigma-Aldrich, St. Louis, MO), aztreonam (Sigma),
cefepime (Sigma), ceftazidime (Sigma), ciprofloxacin
(Sigma), doripenem (Sigma), gentamicin (Amresco
Inc., Solon, OH), imipenem (Sigma), levofloxacin
(Sigma), and meropenem (Sumitomo Pharmaceuticals
Co., Ltd., Osaka, Japan) were determined in duplicate
by the agar dilution method according to the recom-
mendations of the CLSI [17]. P. aeruginosa ATCC
27853 was used as the quality control strain. The in-
terpretation of resistance to these antimicrobial agents
was determined according to the recommendations of
the CLSI [18]. Multidrug resistant (MDR) P. aerugi-
nosa was defined as isolates that were resistant to at
least 3 classes of the tested antimicrobial agents [19].
Pulsed-field gel electrophoresis (PFGE)
PFGE of SpeI-digested genomic DNA samples of P. aer-
uginosa isolates was carried out with a CHEF Mapper
XA apparatus (Bio-Rad Laboratories, Hercules, CA) ac-
cording to the instruction manual. Electrophoresis was
performed for 24 h at 14 °C with pulse time ranging
from 5 to 35 s at 6 V/cm [20]. PFGE profiles were ana-
lyzed and compared using the GelCompar II software,
version 2.0 (Unimed Healthcare Inc., Houston, TX).
β-lactamase characterization
β-lactamase genes (blaCTX-M, blaGES, blaGIM, blaIMP,
blaKPC, blaOXA-1, blaOXA-2, blaOXA-23, blaOXA-40, blaOXA-
48, blaOXA-51, blaOXA-58, blaPSE, blaSHV, blaSIM, blaSPM,
blaTEM, and blaVIM) were detected by PCR [21–30]. The
purified PCR products were directly sequenced using an
automated ABI PRISM 3730 DNA sequencer (Applied
Biosystems, Foster, CA). The DNA sequences and de-
duced amino acid sequences were compared with genes in
the GenBank database (http://www.ncbi.nlm.nih.gov/gen-
bank/) or the β-lactamase classification system (http://
www.lahey.org/studies/) to confirm the subtypes of β-
lactamase genes.
AmpC overproduction was investigated using cloxacil-
lin (250 μg/mL; Sigma)-containing plates, since cloxacil-
lin inhibits AmpC β-lactamase activity and thus restores
susceptibility to ceftazidime [16]. E. cloacae ATCC
13047, which contained AmpC class C β-lactamase, and
ATCC 15337 were used as positive and negative control
strains, respectively [30]. ESACs β-lactamases properties
were determined by using cloxacillin-containing plates
with or without adding imipenem [16]. An isolate was
defined as an AmpC overproducer or having ESACs
phenotype when there was at least a twofold dilution dif-
ference between the MIC of ceftazidime/ceftazidime plus
cloxacillin and the MIC of imipenem/imipenem plus
cloxacillin, respectively. In addition, PCR amplification
of ampC-type genes was performed as previously de-
scribed [16]. The purified PCR products were directly
sequenced using an automated ABI PRISM 3730 DNA
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sequencer (Applied Biosystems, Foster, CA). AmpC se-
quences were compared with that of P. aeruginosa
PAO1 strain (GenBank nucleotide sequence accession
numbers FJ666065).
Detection of efflux pump activity
To investigate the activity of efflux pumps in IRPA iso-
lates, MICs of meropenem in the presence of efflux pump
inhibitors Phe-Arg β-naphthylamide dihydrochloride
(PAβN) (Sigma) or carbonyl-cyanide-m-chlorophenylhy-
drazone (CCCP) (Sigma) were determined [12, 31, 32].
PAβN at 50 μg/mL or 12.5 μM CCCP was incorporated in
MH agar, and meropenem susceptibility testing was per-
formed in parallel on agar plates with or without an efflux
pump inhibitor. P. aeruginosa ATCC 27853 was used as
the control strain.
Analysis of efflux pump genes expression
Overnight cultured bacteria were diluted 1:100 in MH
broth and grown to the late log phase of growth (OD600
~ 0.7). Total RNA was extracted using the acid phenol/
chloroform method and treated with RNase-free DNase
I (Promega, Madison, WI) and RNasin (Promega), ac-
cording to a previous study [33]. RT-qPCR was per-
formed and the expression of the housekeeping proC
gene was used as the internal control for relative quanti-
fication [34]. Oligonucleotide primers to examine the
gene expression of mexA, mexC, mexE, mexX, and proC
were described previously [13, 34]. Isolates were consid-
ered to be MexAB-OprM, MexCD-OprJ, MexEF-OprN,
and MexXY-OprM hyperproducers when the levels of
expression of mexA, mexC, mexE, and mexX were at
least fivefold higher than that of the reference strain P.
aeruginosa PAO1, respectively.
Examination of oprD mutations
The oprD gene of P. aeruginosa was amplified by
PCR, and the primers used were described previously
[6]. oprD sequences were compared with that of the
P. aeruginosa PAO1 strain. Insertion sequences (ISs)
were further identified using the IS Finder database
(http://www-is.biotoul.fr) [35].
Results
Long-term surveillance and antimicrobial susceptibility of
IRPA
Based on the large scale screening of bacteremic P. aeru-
ginosa isolates, 5.9 % of isolates appeared to be resistant
to imipenem. The trend in the prevalence of imipenem-
resistant invasive isolates remained generally stable and
low during this 10-year surveillance. The MICs of the 78
isolates to 10 antimicrobial agents are shown in Table 1.
All isolates were resistant to imipenem but 2 (2.6 %) and
3 (3.8 %) isolates were susceptible to meropenem and
doripenem, respectively. Moreover, the entire collection
was highly susceptible to amikacin (67/78, 85.9 %). No
colistin resistant IRPA isolate was found. A total of 65
(83.3 %) IRPA isolates were defined to be MDR strains.
Pulsed-field gel electrophoresis analysis
PFGE was performed on all collected IRPA isolates ex-
cept isolate 926 showed low resolution (Fig. 1). Using
a > 80 % similarity cut-off point [36], PFGE analysis
showed high genetic heterogeneity in 77 isolates. Only 3
pairs of isolates (9530 and 6883; 3377 and 3056; 1122
and 1164) collected from the same hospital and year
showed genetic relatedness (Fig. 1).
β-lactamase characterization
Genotyping of β-lactamases revealed that VIM-2, VIM-
3, OXA-10, and OXA-17 β-lactamases were identified in
2 (2.6 %), 3 (3.8 %), 2 (2.6 %), and 1 (1.3 %) isolates, re-
spectively. All VIM- and OXA-carrying strains were
classified as MDR-P. aeruginosa (Fig. 1). AmpC overpro-
duction and ESACs were shown in 25 (32.1 %) and 15
(19.2 %) of the 78 IRPA isolates, respectively (Fig. 1).
The AmpC amino acid sequences of 15 ESACs pro-
ducers showed 9 variants from the AmpC sequence of P.
aeruginosa PAO1. The most frequent variant was PDC-3
(4/15, isolates 318, 1164, 6883, and 9530), which con-
tained a T105A substitution, compared to the AmpC of
P. aeruginosa PAO1 (PDC-1) [16]. The PDC-2 (1/15,
Table 1 In vitro activity of 10 antimicrobial agents against 78
bloodstream infection IRPA isolates
Antibiotica MIC (μg/mL) % Susceptibility
Range MIC50 MIC90 S I R
Cephems
Ceftazidime 2–> 128 32 128 29.5 14.1 56.4
Cefepime 2–> 64 32 64 21.8 16.7 61.5
Monobactam
Aztreonam 2–> 64 32 64 24.4 21.8 53.8
Carbapenems
Imipenem 16–256 32 64 0 0 100
Meropenem 1–64 16 32 2.6 9.0 88.4
Doripenem 1–128 16 32 3.8 0 96.2
Aminoglycosides
Amikacin ≤1–> 64 8 32 85.9 5.1 9.0
Gentamicin ≤1–> 256 8 256 33.3 23.1 43.6
Fluoroquinolones
Ciprofloxacin ≤0.5–> 64 2 32 47.4 5.1 47.5
Levofloxacin ≤0.5–> 128 4 64 42.3 9.0 48.7
MIC50/90, minimum inhibitory concentration for 50 % and 90 % of the isolates,
respectively; S, susceptible; I, intermediate resistant; R, resistant
aAll isolates were susceptible to colisin, as determined by the disc
diffusion method
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isolate 7890) and PDC-5 (3/15, isolates 834, 6208, and
9054) variants had the G27D, A97V, T105A, and V205L;
and R79Q and T105A substitutions, respectively. Only 2
isolates (2/15, isolates 1507 and 2432) showed the
identical PAO1 sequence of AmpC. The remaining 5 iso-
lates contained substitutions of AmpC described as fol-
lows: isolate 3377, G27D, T105A, A156T, V205L, and
V356I; isolate 3427, R79Q, T105A, V205L, and V356I;
Fig. 1 PFGE, MICs of carbapenems, and resistant mechanisms among 77 IRPA isolates. One isolate (926) showing low resolution of PFGE was excluded
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isolate 4935, T21A, T105A, and V205L; isolate 6766,
R79Q, T105A, and V205L; and isolate 6861, G27D,
T105A, and V205.
Efflux pump activity
A greater than or equal to fourfold decrease in MIC of
meropenem when tested in combination with either efflux
pump inhibitor, PAβN or CCCP, was shown in 58 (74.4 %)
and 3 (3.8 %) of the IRPA isolates, respectively. This indi-
cates that an active efflux pump contributes to the imipe-
nem resistance of P. aeruginosa isolates. Moreover, PAβN
was effective in changing the isolate categorization from
meropenem resistant (MIC ≥ 8 μg/mL) to susceptible
(MIC ≤ 2 μg/mL) in 40 isolates (40/58, 70 %). Overexpres-
sion of RND efflux pump genes mexA, mexC, mexE, and
mexX were further determined among 29 selected isolates
with greater than or equal to a fourfold concentration
decrease in MIC (from resistant to susceptible) for mero-
penem in combination with PAβN. Among them, no over-
expression of mexA was detected, and only 6 (20.7 %) of
the isolates expressed mexC and mexE at least fivefold
higher than that of the control strain PAO1. Eighteen
(62.1 %) isolates overexpressed mexX at least tenfold
higher than that of PAO1. Nine (31 %) of the 29 isolates
that did not overexpress any of the major RND efflux
pumps were further tested for the susceptibility to 50 μg/
mL of PAβN, and the results showed 1 isolate (532) was
susceptible to PAβN. However, the remaining 8 isolates
possibly contained the additional PAβN-sensitive efflux
pump that reduces the imipenem susceptibility.
Outer membrane protein OprD analysis
The amino acid sequences of OprD from IRPA isolates
were compared with the sequence of the reference strain
PAO1. The results showed that oprD mutations with an
amino acid substitution, shortened putative loop L7, a
premature stop codon by point mutation, a frameshift
by nucleotide insertion or deletion, or interruption by
insertion sequence (IS) were found in 19 (24.4 %), 18
(23.1 %), 15 (19.2 %), 14 (17.9 %), and 10 (12.8 %) iso-
lates, respectively. Only 2 isolates (2.6 %, isolates 926
and 5718) had the identical sequence of the PAO1 oprD
(Table 2). Moreover, 7 IRPA isolates (669, 809, 877, 930,
1404, 3056, and 5276) contained only an oprD mutation
but not other mechanisms associated with imipenem re-
sistance (Fig. 1).
A shortened putative loop L7 of OprD was found in
18 isolates (23.1 %) (MIC ranges of imipenem, merope-
nem, and doripenem were 16-64, 1-64, and 1-64 μg/mL,
respectively) (Fig. 1). Additive amino acid substitutions
of OprD were found in all these 18 IRPA. In addition,
isolates 472, 662, 6883, 8006, and 9530 contained identi-
cal 15 amino acid substitutions and a shortened loop L7
of OprD. Isolate 1404, with a shortened loop L7 alone,
showed lower MICs of meropenem (1 μg/mL) and dori-
penem (1 μg/mL); the remaining 11 isolates had a short-
ened loop L7 in combination with AmpC and ESAC
overproduction or active efflux overexpression and
showed higher MICs of meropenem (4–64 μg/mL) and
doripenem (2–32 μg/mL) (Fig. 1). The amino acid vari-
ation of isolate 1404 contributed to its low level resist-
ance to imipenem (MIC, 16 μg/mL).
Table 2 oprD genotypes among 78 bacteremic IRPA isolates
Major types of mutationa No. of isolate Description
Amino acid frameshift produced by 1- and 2-bp
insertion or deletion
10 Deletion of: 1 bp (G) at nt 311; 2 bp (TG) at nt 407-408; 1 bp (C) at
nt 456 (2 isolates)
Insertion of: 1 bp (G) at nt 555; 1 bp (T) at nt 977; 2 bp (AC) at nt
1050-1051 (2 isolates); 1 bp (C) at nt 1205 (2 isolates)
Amino acid frameshift produced by partial deletion 5 11-bp deletion beginning at nt 140, nt 175, nt 473
13-bp deletion beginning at nt 175, nt 208
Premature stop codon (point mutation) 14 CAG→ TAG at nt 55-57, nt 472-474, nt 883-885, nt 1270-1272 (3 isolates)
TGG→ TAG at nt 193-195
TGG→ TAG at nt 829-831 (3 isolates)
TGG→ TGA at nt 829-831
TGG→ TAG at nt 1015-1017 (2 isolates)
TAT→ TAG at nt 1048-1050
Interruption by IS 10 Transposase at nt 37, 50 (2 isolates), 271, 434, 562, 571, 623, 652, 694
Amino acid substitution 19 Polymorphisms: D43N, S57E, S59R, T103S, K115T, V127L, F170L, E185Q,
P186G, V189T, E202Q, I210A, E230K, D231N, S240T, L246V, D249E, L252V,
N262T, R310E, A315G, S403A, Q424E, and G425A
Shortening of putative loop L7 18 Putative loop L7 (372 V-DSSSSYAGL-Y384)
Identical 2 -
aOnly 2 isolates (926 and 5718) showed identical sequences of oprD to PAO1. The other 76 isolates contained amino acid variation compared to the sequence of
oprD in PAO1
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The sequencing results showed that 6 IS elements,
including ISPa47 (isolates 1406 and 2432), ISPa1635
(isolates 1220 and 1333), IS6110 (isolates 1164 and
1529), ISPa52 (isolates 877 and 1307), ISPpu21
(isolate 4055), and ISAzo11 (isolate 572), were identi-
fied in 10 IRPA isolates, and thus lead to a disruption
of the coding sequence of OprD (Fig. 1). Among
these IS elements, ISPa47, ISPa1635, and IS6110,
were classified as IS family IS6330, IS4, and IS6, re-
spectively. ISPa52, ISPpu21, and ISAzo11 were classi-
fied as IS5 transposase family. No novel IS element
was found in our IRPA isolates.
Discussion
In the present study, we showed the prevalence of imi-
penem resistance in bacteremic P. aeruginosa is 5.9 %
during a 10-year longitudinal surveillance in Taiwan.
Mutations in oprD and an active efflux pump are the
major causes of imipenem resistance, followed by over-
production of AmpC β-lactamase, ESACs phenotype,
and the acquisition of VIM- and OXA-β-lactamases in
P. aeruginosa.
Surveillance of antimicrobial susceptibility by the
SMART 2008 reported that the susceptibility to imipe-
nem of P. aeruginosa from intra-abdominal infections
was 69 % worldwide [9]. Another global multicenter sur-
veillance study, Tigecycline Evaluation and Surveillance
Trial (TEST), showed that the imipenem resistance rate
of blood isolates of P. aeruginosa collected from 2004
until August 2009 was 7.4 % [8]. Recently, carbapenem
resistance of invasive P. aeruginosa has rising to 17.1 %,
which was reported from the European Centre for Dis-
ease Prevention and Control 2012 [11]. Lin et al. showed
the overall prevalence of CRPA was 10.2 % in Taiwan,
and there was a significant trend of increasing CRPA
prevalence during the period 2000-2010 [10]. However,
our results showed lower prevalence (5.9 %) of
bacteremic CRPA isolates in Taiwan. Moreover, the en-
tire collection was highly susceptible to amikacin (67/78,
85.9 %) and no colistin resistant IRPA isolate was found.
As a result, amikacin and colistin can serve as treatment
agents against bacteremic IRPA in Taiwan. However, car-
bapenem susceptibility of invasive P. aeruginosa infec-
tions needs to be continually monitored to control the
prevalence of CRPA.
The active efflux pumps in P. aeruginosa belonging to
the RND family, which contributes to multidrug resist-
ance by extruding the antimicrobial agents outside the
bacterial cells [37]. Overexpression of the RND efflux
pump systems MexAB-OprM, MexCD-OprJ, MexEF-
OprN, and MexXY-OprM confer resistance to carba-
penem in P. aeruginosa [2, 12, 13]. In this study, the
mexA is constitutively expressed in all of the tested iso-
lates with active efflux, and no difference among
imipenem resistant isolates was found, compared with P.
aeruginosa PAO1. This indicates that mexA contributes
a limited role to imipenem resistance in our isolates.
The mexC, mexE, and mexX are expressed at a low level
in late log phase in PAO1, but their expression is more
than fivefold up-regulated in 6 (20.7 %), 6 (20.7 %), and
18 (62.1 %) of 29 selected resistant strains, respectively.
Therefore, our data demonstrated the importance of ef-
flux pump systems in the imipenem resistance of P. aer-
uginosa. However, 8 isolates which possibly contained
unknown PAβN-sensitive efflux pumps that reduce imi-
penem susceptibility remained to be investigated.
The outer membrane protein OprD, a carbapenem-
specific porin, contributed to imipenem resistance
and reduced susceptibility to meropenem in P. aerugi-
nosa [5, 6, 38]. Mutations of oprD prevalent in our
isolates revealed that loss or reduced OprD confers
resistance to carbapenem in P. aeruginosa (Fig. 1). A
shortened putative loop L7 of the OprD porin was
identified in carbapenem-resistant isolates, and this
shortening may open the porin channel to allow opti-
mal penetration of meropenem and increase the mer-
openem susceptibility profile in imipenem-resistant P.
aeruginosa [6, 38]. We also found a shortened loop
L7 of the OprD in 18 IRPA isolates, and strain 1404,
with only a shortened loop L7, showed lower MICs
of meropenem (1 μg/mL) and doripenem (1 μg/mL),
compared with strains had shortened loop L7 and the
presence of AmpC and ESAC overproduction or ac-
tive efflux (4–64 μg/mL). A lower MIC of doripenem
in strains with a shortened loop L7 of OprD was also
observed (Fig. 1). This raises the possibility that a
shortened loop L7 of the OprD porin is responsible
for the unusual meropenem and doripenem hypersus-
ceptibility. Moreover, Riera et al. showed that while
the inactivation of the porin OprD caused high-level
resistance to imipenem (MIC > 32 μg/mL), it pro-
duced only moderate resistance to meropenem [7],
and these results are observed in this study (Fig. 1).
Yan et al. have reported the presence of unusual bla-en-
coding integrons of VIM-2, VIM-3, OXA-10, and OXA-17
in multidrug-resistant P. aeruginosa isolates in Taiwan
[28]. In the present study, all 8 VIM- and OXA-carrying
isolates belonged to MDR P. aeruginosa. Although the
imipenem resistance mechanisms in our isolates are
diverse, isolates harboring VIM- and OXA-type β-
lactamases showed higher carbapenem MICs, especially
imipenem (32–256 μg/mL) (Fig. 1). This reflects that car-
bapenem can be efficiently hydrolyzed by the VIM- and
OXA-type β-lactamases [5, 12].
Increased production of the AmpC chromosome-
encoded cephalosporinase and ESACs production
contributed to carbapenem resistance in P. aeruginosa
[2, 5, 7, 13, 16]. In this study, we used the AmpC
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inhibitor cloxacillin to demonstrate that AmpC overpro-
duction and ESAC were shown in 25 (32.1 %) and 15
(19.2 %) of the IRPA strains, respectively. The prevalence
of the AmpC and ESAC phenotypes in our isolates was
lower than the reported by Rodríguez-Martínez et al.
(78 % and 72 %) [16], and we revealed that overproduc-
tion of AmpC and ESAC play an additive role in reduced
susceptibility to carbapenem in our resistant strains.
Moreover, 88.2 % (30/34) of AmpC or ESAC overprodu-
cers were MDR strains, indicating that overexpression of
AmpC and ESAC is an important issue for antibiotic re-
sistance in P. aeruginosa. Thirteen out of 15 isolates
contained an AmpC β-lactamase variant, with all vari-
ants possessing an alanine residue at position 105. This
residue had been previously shown to be the key factor
for an ESAC phenotype [16]. However, 2 isolates (1507
and 2432) were ESAC producers containing the identical
PAO1 (PDC-1) sequence of AmpC. As a result, the
mechanism leading to the EASC property in these two
isolates remained to be clarified.
Conclusions
In conclusion, imipenem resistance in bacteremic P. aer-
uginosa collected between January 2000 and February
2010 remained low (5.9 %) in Taiwan. Mutations of oprD
and active efflux are the major causes of imipenem re-
sistance. Overproduction of AmpC β-lactamase, ESAC,
and acquisition of VIM and OXA are also involved in
imipenem resistance of P. aeruginosa. Since 83.3 % of
imipenem-resistant isolates were found to be MDR
strains, usage of carbapenems should be controlled to
prevent pan-drug resistant P. aeruginosa occurrence.
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